Meta-Analysis of 550,385 Participants Quantifies Cardiotoxicity in Leukemia and Lymphoma

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  BMC Cancer. https://doi.org/10.1186/s12885-026-16294-7  
Dr. Siqing Liu et al.

Points

Hangzhou Normal University investigators performed a comprehensive meta-analysis pooling fifty global studies to determine the precise correlation between historical hematologic malignancies and subsequent cardiovascular disease development.
Statistical screening of 550,385 unique participants tracked across multiple decades confirmed that leukemia survivors experience a significantly elevated relative risk of 2.68 for total cardiovascular complications.
Long-term cardiotoxic profiling revealed that patients recovering from leukemia exhibit a relative risk of 4.13 for heart failure and a relative risk of 3.05 for ischemic stroke.
Comparative treatment evaluations proved that radiotherapy-treated individuals experience a relative risk of 4.06, which is dramatically higher than the 2.12 risk observed in patients undergoing chemotherapy alone.
Clinical investigators concluded that healthcare providers must prioritize robust, lifelong cardiovascular screening and preventative management to mitigate delayed treatment-induced vascular and myocardial degradation in cancer survivors.

Summary

Executed to synthesize multi-decade cardiotoxic profiles across hematologic malignancies, this meta-analysis quantified the delayed risk of cardiovascular disease (CVD) in survivors of leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma. As modern therapeutic protocols steadily optimize long-term survivorship, an aging cohort of patients has emerged with an expanded lifespan but a heightened vulnerability to treatment-induced or carcinogenesis-associated cardiotoxicity. The research sought to resolve inconsistent prospective findings by establishing definitive pooled relative risks for specific, long-term cardiovascular phenotypes.

Aggregating data from 50 distinct clinical studies encompassing 550,385 unique participants, investigators analyzed datasets spanning 1940 to 2020 for leukemia cohorts and 1940 to 2016 for lymphoma sub-populations. Statistical processing of fully adjusted models demonstrated that survivors of leukemia face a heavily elevated pooled risk for multiple life-threatening cardiovascular events compared to the general population. Specifically, the analysis identified a relative risk (RR) of 2.68 for total CVD, 1.46 for ischemic heart disease, 4.13 for heart failure, and 3.05 for stroke, with highly similar positive associations universally recorded across both Hodgkin and non-Hodgkin lymphoma survivors.

Therapeutic modalities significantly stratified subsequent cardiotoxic outcomes within the pooled validation cohort, exposing clear clinical disparities between intervention designs. Compared to cancer survivors who underwent standard chemotherapy regimens alone (RR = 2.12) individuals managed with localized or systemic radiotherapy exhibited a vastly superior propensity for cardiovascular degradation, demonstrating a pooled relative risk of 4.06. These findings suggest that implementing aggressive, lifelong cardiovascular screening protocols represents a highly viable post-malignancy triage strategy, allowing clinicians to deploy early cardioprotective interventions and mitigate severe delayed treatment complications.

Link to the article: https://link.springer.com/article/10.1186/s12885-026-16294-7

References

Liu, S., Liu, S., Hu, Y., Deng, J., Sun, G., & Fang, X. (2026). Long-term cardiovascular risk in survivors of hematologic malignancies: A meta-analysis. BMC Cancer. https://doi.org/10.1186/s12885-026-16294-7